Search results for "PROGRESS"

showing 10 items of 1620 documents

Hypothesis: Etiologic and Molecular Mechanistic Leads for Sporadic Neurodegenerative Diseases Based on Experience With Western Pacific ALS/PDC

2019

Seventy years of research on Western Pacific amyotrophic lateral sclerosis and Parkinsonism-dementia Complex (ALS/PDC) have provided invaluable data on the etiology, molecular pathogenesis and latency of this disappearing, largely environmental neurodegenerative disease. ALS/PDC is linked to genotoxic chemicals (notably methylazoxymethanol, MAM) derived from seed of the cycad plant (Cycas spp.) that were used as a traditional food and/or medicine in all three disease-affected Western Pacific populations. MAM, nitrosamines and hydrazines generate methyl free radicals that damage DNA (in the form of O6-methylguanine lesions) that can induce mutations in cycling cells and degenerative changes …

0301 basic medicineamyotrophic lateral sclerosisDNA damageDiseaseBiologylcsh:RC346-429Environmental - originProgressive supranuclear palsy03 medical and health sciences0302 clinical medicineHypothesis and TheorymedicinenitrosaminesAmyotrophic lateral sclerosislcsh:Neurology. Diseases of the nervous systemhydrazinesprogressive supranuclear palsymedicine.diseaseatypical parkinsonism030104 developmental biologyBrain degenerationNeurologyImmunologyEtiologycycad methylazoxymethanol and L-BMAADNA damageNeurology (clinical)Alzheimer's diseaseAlzheimer disease030217 neurology & neurosurgeryFrontiers in Neurology
researchProduct

FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial

2018

Abstract Aim of the study The optimal therapeutic strategy in patients with rectal cancer and synchronous unresectable metastases remains unknown. We evaluated the efficacy of FOLFIRINOX induction therapy in this setting. Patients and methods Chemotherapy-naive patients received at least 8 cycles of FOLFIRINOX. The primary end-point was the 4-month disease control (4 m DC) rate. Tumour responses were centrally reviewed and assessed by computed tomography scan for metastases (Response Evaluation Criteria in Solid Tumours criteria) and magnetic resonance imaging for rectal tumorus. With a Simon 2-stage design and a targeted (H1) 4 m DC > 75%, 65 patients were enrolled from July 2012 to Februa…

MaleCancer ResearchLung NeoplasmsColorectal cancerFOLFIRINOXGastrointestinal DiseasesSynchronous metastasesLeucovorinKaplan-Meier EstimateInduction0302 clinical medicineInduction therapyAntineoplastic Combined Chemotherapy ProtocolsRectal cancerINDUCTION TREATMENTFatigueResponse rate (survey)medicine.diagnostic_testLiver NeoplasmsRemission InductionMiddle AgedCombined Modality TherapyMagnetic Resonance ImagingProgression-Free Survival3. Good healthOxaliplatinFOLFIRINOXTreatment OutcomeOncology030220 oncology & carcinogenesis030211 gastroenterology & hepatologyFemaleRadiologyFluorouracilAdultmedicine.medical_specialty[SDV.CAN]Life Sciences [q-bio]/CancerAdenocarcinomaIrinotecan03 medical and health sciencesmedicineHumansParesthesiaAgedPerformance statusbusiness.industryRectal NeoplasmsMagnetic resonance imagingmedicine.diseaseHematologic DiseasesConfidence intervalLocal controlbusinessTomography X-Ray ComputedFollow-Up Studies
researchProduct

Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study

2015

EA Pôle MERS Hors CT hors EJ; International audience; Background & Aims: To compare the management of chronic hepatitis B (CHB) and its evolution over time in currently followed HIV-positive and HIV-negative patients. Methods: A total of 709 consecutive patients with past or present positive HBs antigenemia seen in October 2012 in 19 French participating centres were included. The data were retrospectively collected from the first visit onwards through standardized questionnaires. Results: Chronic hepatitis B was less often assessed in the 299 HIV-positive patients, who were older, more likely to be male, excessive alcohol drinkers and HBe antigen-, HCV- and HDV-positive. They were also fol…

Liver CirrhosisMale[SDE] Environmental SciencesCirrhosis[SDV]Life Sciences [q-bio]HIV InfectionsComorbidityCohort Studies0302 clinical medicineReference ValuesHIV SeropositivityHBV[SDV.BV] Life Sciences [q-bio]/Vegetal Biology030212 general & internal medicineHIV SeronegativityLiver NeoplasmsLamivudinevirus diseasesEntecavirhepatocellular carcinomaMiddle Aged3. Good health[SDV] Life Sciences [q-bio]Treatment OutcomeLamivudineHepatocellular carcinoma[SDE]Environmental SciencesDisease ProgressionFemale030211 gastroenterology & hepatologyFranceCohort studymedicine.drugAdultmedicine.medical_specialtyGuanineAntiviral AgentsRisk AssessmentStatistics Nonparametric03 medical and health sciencesHepatitis B ChronicHIV SeronegativityInternal medicinemedicineHumans[SDV.BV]Life Sciences [q-bio]/Vegetal BiologySurvival analysisRetrospective StudiesHepatitis B Surface AntigensHepatologybusiness.industrycirrhosisHIVmedicine.diseaseSurvival AnalysisComorbiditytenofovirLogistic ModelsMultivariate AnalysisImmunologybusinessentecavir
researchProduct

Manometric assessment of oesophageal involvement in progressive systemic sclerosis, morphoea and Raynaud's disease.

1982

SUMMARY Oesophageal function was studied by radiography and manometry in fifty-one patients with progressive systemic sclerosis (PSS), fourteen patients with morphoea, twelve patients with Raynaud's disease and twenty-one normal subjects. Upper oesophageal sphincter pressure was not affected. Peristaltic contractions of the upper third of the oesophagus were significantly decreased in PSS and morphoea, but the lower two-thirds were affected only in PSS. Lower oesophageal sphincter pressure was significantly decreased in PSS but was normal in morphoea and Raynaud's disease. There was a significant correlation between oesophageal dysfunction and the duration of PSS. Manometry was better than …

musculoskeletal diseasesAdultMalemedicine.medical_specialtyTime FactorsOesophageal manometryAdolescentManometryRadiographyDermatologySkin DiseasesScleroderma LocalizedEsophagusstomatognathic systemLower oesophageal sphincter pressurePressureMedicineUpper oesophageal sphincter pressureHumansAgedScleroderma Systemicbusiness.industryProgressive systemic sclerosisRaynaud DiseaseMiddle Agedmedicine.diseaseeye diseasesRadiographystomatognathic diseasesRaynaud's diseaseFemaleUpper thirdRadiologyOesophageal functionbusinessThe British journal of dermatology
researchProduct

The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma

2016

// Alessandra Romano 1 , Nunziatina Laura Parrinello 1 , Calogero Vetro 1 , Daniele Tibullo 1 , Cesarina Giallongo 1 , Piera La Cava 1 , Annalisa Chiarenza 1 , Giovanna Motta 1 , Anastasia L. Caruso 1 , Loredana Villari 2 , Claudio Tripodo 3 , Sebastiano Cosentino 4 , Massimo Ippolito 4 , Ugo Consoli 5 , Andrea Gallamini 6 , Stefano Pileri 7 , Francesco Di Raimondo 1 1 Division of Hematology, AOU “Policlinico - Vittorio Emanuele”, University of Catania, Catania, Italy 2 Division of Pathology, AOU “Policlinico - Vittorio Emanuele”, Catania, Italy 3 Tumor Immunology Unit, Department of Health Science, University of Palermo, Palermo, Italy 4 Nuclear Medicine Center, Azienda Ospedaliera Cannizz…

0301 basic medicineMaleCancer ResearchMyeloidNeutrophilsmedicine.medical_treatmentArginase-1Treatment outcomeKaplan-Meier EstimateGastroenterology0302 clinical medicineHematologyHealthy subjectsImmunosuppressionHematologyMiddle AgedPrognosisHodgkin DiseaseTreatment Outcomemedicine.anatomical_structureOncology030220 oncology & carcinogenesisFemaleArginase-1; Hodgkin Lymphoma; PET-2Tumor immunologyResearch PaperAdultmedicine.medical_specialtyPrognostic variableAdolescentAntineoplastic AgentsPET-2Sensitivity and SpecificityDisease-Free SurvivalYoung Adult03 medical and health sciencesInternal medicineBiomarkers TumormedicineHumansProgression-free survivalAgedArginasebusiness.industryMyeloid-Derived Suppressor Cells030104 developmental biologyPotential biomarkersImmunologyHodgkin lymphomabusinessHodgkin lymphoma030215 immunologyOncotarget
researchProduct

Increased regulatory T-cell frequencies in patients with advanced melanoma correlate with a generally impaired T-cell responsiveness and are restored…

2009

Naturally occurring CD4(+) CD25(+) regulatory T-cell (Treg) activity is assumed to facilitate tumor development and progression. To elucidate the possible role of Tregs in the course of melanoma progression, we analysed the frequency of Tregs in the peripheral blood of patients at melanoma stages I-IV and in patients at melanoma stage IV that underwent dendritic cell (DC)-based immunotherapy. Using CD25, Foxp3, CD127 and HLA-DR as Treg associated markers, we observed increased Treg frequencies in patients at the late melanoma stage (stage IV) when compared to healthy donors. Accumulation of Tregs in patients with progressed melanoma correlated with a general reduction of T-cell responsivene…

Regulatory T cellbusiness.industryT cellmedicine.medical_treatmentMelanomaFOXP3hemic and immune systemschemical and pharmacologic phenomenaDermatologyImmunotherapyDendritic cellmedicine.diseaseBiochemistrymedicine.anatomical_structureTumor progressionImmunologymedicineIL-2 receptorbusinessMolecular BiologyExperimental Dermatology
researchProduct

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy

2018

Purpose This multicenter phase II trial evaluated lurbinectedin (PM01183), a selective inhibitor of active transcription of protein-coding genes, in patients with metastatic breast cancer. A unicenter translational substudy assessed potential mechanisms of lurbinectedin resistance. Patients and Methods Two arms were evaluated according to germline BRCA1/2 status: BRCA1/2 mutated (arm A; n = 54) and unselected ( BRCA1/2 wild-type or unknown status; arm B; n = 35). Lurbinectedin starting dose was a 7-mg flat dose and later, 3.5 mg/m2 in arm A. The primary end point was objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST). The translational substudy of resist…

Adult0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyGenes BRCA2Genes BRCA1Phases of clinical researchAntineoplastic AgentsBreast NeoplasmsHeterocyclic Compounds 4 or More RingsMice03 medical and health sciences0302 clinical medicineGermline mutationInternal medicineBiomarkers TumorClinical endpointAnimalsHumansMedicineProgression-free survivalGerm-Line MutationAgedDose-Response Relationship DrugErratabusiness.industryMiddle Agedmedicine.diseaseXenograft Model Antitumor AssaysMetastatic breast cancerProgression-Free SurvivalClinical trial030104 developmental biologyOncologyResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisBiomarker (medicine)FemalebusinessCarbolinesJournal of Clinical Oncology
researchProduct

Age of onset of Cannabis use and cognitive function in first-episode non-affective psychosis patients: Outcome at three-year follow-up

2018

In recent years, the effects of cannabis use on cognitive functions in patients with psychosis have been widely studied. Recently, special emphasis has been placed on the impact of age at the onset of consumption on cognition in these patients.349 patients with a first episode of non-affective psychosis were studied. Patients were classified as cannabis users and non-users. Users were divided, according to their age when they began using cannabis, into: early-onset (age  16) and late-onset (age ≥ 16) users. Differences between groups at baseline were studied based on sociodemographic, clinical, and cognitive variables. The groups were longitudinally (3-year) compared on cognitive variables.…

AdultMaleMarijuana AbusePsychosismedicine.medical_specialty030508 substance abuseYoung Adult03 medical and health sciencesCognition0302 clinical medicineMemoryHumansMedicineLongitudinal StudiesAge of OnsetPsychiatryBiological PsychiatryEffects of cannabisFirst episodebiologybusiness.industryCognitionbiology.organism_classificationmedicine.diseasePsychiatry and Mental healthCross-Sectional StudiesPsychotic DisordersDisease ProgressionSpeech PerceptionFemaleMarijuana UseCannabisVerbal memoryAge of onset0305 other medical sciencebusinessNeurocognitive030217 neurology & neurosurgeryFollow-Up StudiesSchizophrenia Research
researchProduct

Genetic similarity of hepatitis C virus and fibrosis progression in chronic and recurrent infection after liver transplantation

2006

SUMMARY. The effect of hepatitis C virus (HCV) genetic heterogeneity on clinical features of post-transplantation hepatitis C is controversial. Different regions of the HCV genome have been associated with apoptosis, fibrosis, and other pathways leading to liver damage in chronic HCV infection. Besides, differences in immunodominant regions, such as NS3, may influence HCV-specific immune responses and disease outcome. In the liver transplant setting, a recent study has reported a positive association between HCV-1b Core region genetic relatedness 5-year post-transplantation and histological severity of recurrent hepatitis C. We have compared nucleotide sequences of HCV Core, NS3 and NS5b re…

Liver CirrhosisMaleCirrhosisBiopsyHepatitis C virusmedicine.medical_treatmentGenome ViralHepacivirusViral Nonstructural ProteinsLiver transplantationBiologymedicine.disease_causeVirusCohort StudiesSpecies SpecificityRecurrenceFibrosisVirologymedicineHumansHepatologySequence Analysis RNAGenetic heterogeneityViral Core Proteinsvirus diseasesHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseasedigestive system diseasesLiver TransplantationChronic infectionInfectious DiseasesLiverSpainImmunologyDisease ProgressionFemaleJournal of Viral Hepatitis
researchProduct

Dystrophin-deficiency increases the susceptibility to doxorubicin-induced cardiotoxicity

2007

Background and aim: The clinical use of doxorubicin (DOX) and other anthracyclines is limited by a dosage-dependent cardiotoxicity, which can lead to cardiomyopathy. The role of the individual genetic makeup in this disorder is poorly understood. Alterations in genes encoding cardiac cytoskeleton or sarcolemma proteins may increase the susceptibility to doxorubicin-related cardiotoxicity. Methods: Female dystrophin-deficient mice (MDX) and age-matched wild-type mice underwent chronic treatment with doxorubicin. Cardiac function and tissue damage were assessed by echocardiography and histopathology, respectively. Gene expression changes were investigated using microarrays. Results: DOX treat…

Cardiac function curveProgrammed cell deathPathologymedicine.medical_specialtyHeart DiseasesCytoskeleton organizationCardiomyopathyGene Expression030204 cardiovascular system & hematologyDystrophinMice03 medical and health sciences0302 clinical medicineRisk FactorsmedicineAnimalsDoxorubicinUltrasonography030304 developmental biology0303 health sciencesCardiotoxicityAntibiotics AntineoplasticSarcolemmabiologybusiness.industryGenetic VariationMicroarray Analysismedicine.disease3. Good healthDoxorubicinDisease Progressionbiology.proteinCancer researchFemaleDisease SusceptibilityCardiology and Cardiovascular MedicineDystrophinbusinessmedicine.drugEuropean Journal of Heart Failure
researchProduct